Radio Waves, Real Results: Inside NeuroEM’s Alzheimer’s Moonshot

In this episode of StartUp Health NOW, we dive into one of the most fascinating innovation stories in health tech. Our guest is Chuck Papageorgiou, CEO of NeuroEM Therapeutics, a company that’s part of StartUp Health’s Alzheimer’s Moonshot Community and is making waves with a radically different approach to treating Alzheimer’s disease — using radio waves.

What started as a research study to prove that cell phones cause brain cancer led to an unexpected breakthrough: the very same radio frequencies used in phones appeared to improve brain health in mice with Alzheimer’s. The discovery sparked a scientific journey that has since included promising human trials, FDA Breakthrough Device designation, partnerships, and progress towards bringing this non-invasive, affordable, at-home therapy to millions.

Papageorgiou shares how NeuroEM’s wearable headset is helping untangle the brain’s toxic proteins, the science behind this counterintuitive tech, and why the impact could rival — or even surpass — that of current Alzheimer’s drugs.

If you’re looking for an inspiring story about accidental genius ideas, bold leadership, and breakthrough innovation in brain health, this one’s a must-listen.

Are you ready to tell YOUR story? Members of our Health Moonshot Communities are leading startups with breakthrough technology-driven solutions for the world’s biggest health challenges. Exposure in StartUp Health Media to our global audience of investors and partners – including our podcast, newsletters, magazine, and YouTube channel – is a benefit of our Health Moonshot Community Membership. To schedule a call and see if you qualify to join and increase brand awareness through our multi-media storytelling efforts, submit our three-minute application. If you’re mission-driven, collaborative, and ready to contribute as much as you gain, you might be the perfect fit.
» Learn more and apply today.

Want more content like this? Sign up for StartUp Health Insider™ to get funding insights, news, and special updates delivered to your inbox.